Ronsein, Graziella Eliza 
; Reyes Soffer, Gissette; He, Yi; Oda, Michael; Ginsberg, Henry; Heinecke, Jay W
Source: Molecular e Cellular Proteomics. Unidade: IQ
Subjects: APOLIPOPROTEÍNAS, LIPOPROTEÍNAS HDL, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RONSEIN, Graziella Eliza et al. Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone. Molecular e Cellular Proteomics, v. 15, n. 3, p. 1083-1093, 2016Tradução . . Disponível em: https://doi.org/10.1074/mcp.M115.054528. Acesso em: 06 nov. 2024.APA
Ronsein, G. E., Reyes Soffer, G., He, Y., Oda, M., Ginsberg, H., & Heinecke, J. W. (2016). Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone. Molecular e Cellular Proteomics, 15( 3), 1083-1093. doi:10.1074/mcp.M115.054528NLM
Ronsein GE, Reyes Soffer G, He Y, Oda M, Ginsberg H, Heinecke JW. Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone [Internet]. Molecular e Cellular Proteomics. 2016 ; 15( 3): 1083-1093.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1074/mcp.M115.054528Vancouver
Ronsein GE, Reyes Soffer G, He Y, Oda M, Ginsberg H, Heinecke JW. Targeted proteomics identifies Paraoxonase/Arylesterase 1 (PON1) and apolipoprotein Cs as potential risk factors for hypoalphalipoproteinemia in diabetic subjects treated with fenofibrate and rosiglitazone [Internet]. Molecular e Cellular Proteomics. 2016 ; 15( 3): 1083-1093.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1074/mcp.M115.054528
